Anti-Müllerian hormone (AMH) as part of the diagnostic polycystic ovary syndrome (PCOS) workup in large epidemiological studies
Authors' conclusion
Anti-Müllerian hormone could be useful surrogate for PCOM in large data sets, where transvaginal ultrasound is not feasible, to aid the capturing of women with typical PCOS characteristics. Anti-Müllerian hormone measurement from archived samples enables retrospective PCOS diagnosis when combined with oligo/amenorrhoea or hyperandrogenism.
Study context
- Population
- Women of a general population-based birth cohort with serum AMH measured at age 31 years (Elecsys), combined with oligo/amenorrhoea and hyperandrogenism data
- Participants
- 2,917 women
- Exposure
- AMH cut-off of 10.35 ng/mL (97.5% quartile) vs 3.2 ng/mL as polycystic ovarian morphology (PCOM) surrogate for PCOS diagnosis
- Outcome
- Prevalence of PCOS (Rotterdam criteria) with AMH as surrogate for PCOM, by AMH cut-off
- Follow-up
- Age 31 years
Methodological detailsgeneral population-based
- General population-based
Main finding
As reported in the abstract
PCOS prevalence
Observational data: associations, not effects.
Further findings
Distribution of PCOS phenotypes with AMH cut-off 3.2 ng/mL
- Phenotype A
- 23.9%
- Phenotype B
- 4.7%
- Phenotype C
- 36.6%
- Phenotype D
- 34.8%
Hormonal and metabolic features vs controls
- All PCOS groups (all AMH cut-offs) had significantly higher T, free androgen index (FAI), luteinizing hormone (LH), LH/FSH ratio, body mass index (BMI), waist circumference and homoeostatic model assessment of insulin resistance (HOMA-IR), and significantly lower sex hormone-binding globulin (SHBG) vs controls
Original publication
AMH as part of the diagnostic PCOS workup in large epidemiological studies. Eur J Endocrinol. Published 9 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →